(3S,8S,9S,10R,13R,14S,17R)-10,13-二甲基-17-[(2R)-5-甲基己烷-2-基]-2,3,4,7,8,9,11,12,14,15,16,17-十二氢-1H-环戊二烯并[a]菲-3-醇 | 38819-44-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: (3S,8S,9S,10R,13R,14S,17R)-10,13-二甲基-17-[(2R)-5-甲基己烷-2-基]-2,3,4,7,8,9,11,12,14,15,16,17-十二氢-1H-环戊二烯并[a]菲-3-醇
• 英文名称: 20(R)-(3'-methyl)butyl-5-pregnen-3β-ol
• 英文别名: (+)-cholesterol；cholesterol；halosterol；24-Norcholesterol；(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-5-methylhexan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
• CAS: 38819-44-2
• 化学式: C₂₆H₄₄O
• 分子量: 372.635
• InChiKey: VQSNHPSNPFDOJF-XSLNCIIRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.2
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (3S,8S,9S,10R,13R,14S,17R)-10,13-二甲基-17-[(2R)-5-甲基己烷-2-基]-2,3,4,7,8,9,11,12,14,15,16,17-十二氢-1H-环戊二烯并[a]菲-3-醇 、 苯甲酸酐 在 molybdenium(VI) dioxodichloride 作用下， 以 二氯甲烷 为溶剂， 反应 74.5h， 以92%的产率得到benzoic acid 17-(1,5-dimethylhexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenathren-3-yl ester
  参考文献：
  名称：

  Nucleophilic Acyl Substitutions of Anhydrides with Protic Nucleophiles Catalyzed by Amphoteric, Oxomolybdenum Species

  摘要：

  [GRAPHICS]Among six different group VIb oxometallic species examined, dioxomolybdenum dichloride and oxomolybdenum tetrachloride were the most efficient catalysts to facilitate nucleophilic acyl substitution (NAS) of anhydrides with a myriad array of alcohols, amines, and thiols in high yields and high chemoselectivity. In contrast to the well-recognized redox chemical behaviors associated with oxomolybdenum(VI) species, the catalytic NAS was unprecedented and tolerates virtually all kinds of functional groups. By using benzoic anhydride as a mediator for in situ generation of an incipient mixed anhydride -MoO2Cl2 adduct with a given functional alkanoic acid, one can achieve oleate, dipeptide, diphenylmethyl, N-Fmoc-alpha-amino, pyruvic, and tert-butylthio ester, N-tert-butylamide, and trityl methacrylate syntheses with appropriate protic nucleophiles. The amphoteric character of the Mo=O unit in oxomolybdenum chlorides was found to be responsible for the catalytic NAS profile as supported by a control NAS reaction of using an authentic adduct-MoOCl2(O-2-CBut)(2) between pivalic anhydride and MoO2Cl2 as the catalyst.

  DOI：

  10.1021/jo048363v
• 作为产物：
  描述：

  acetic acid 17-(1,5-dimethylhexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenathren-3-yl ester 生成 (3S,8S,9S,10R,13R,14S,17R)-10,13-二甲基-17-[(2R)-5-甲基己烷-2-基]-2,3,4,7,8,9,11,12,14,15,16,17-十二氢-1H-环戊二烯并[a]菲-3-醇
  参考文献：
  名称：

  Metayer; Barbier, Bulletin de la Societe Chimique de France, 1972, vol. 9, p. 3625 - 3626

  摘要：

  DOI：

文献信息

• [EN] POLYNUCLEOTIDES FOR DISRUPTING IMMUNE CELL ACTIVITY AND METHODS OF USE THEREOF<br/>[FR] POLYNUCLÉOTIDES SERVANT À PERTURBER L'ACTIVITÉ DE CELLULE IMMUNITAIRE ET PROCÉDÉS POUR LES UTILISER
  申请人：MODERNATX INC

  公开号：WO2020227510A1

  公开（公告）日：2020-11-12

  The disclosure features isolated polynucleotides, such as mRNAs, encoding a polypeptide that disrupts immune cell activity, such as T cell or B cell activity, including mRNAs comprising one or more modified nucleobase. The immune cell disruptor polynucleotides encode a polypeptide that comprises a first domain that mediates association of the polypeptide with an immune cell component and a second domain that mediates inhibition of immune cell activity when the polypeptide is expressed in the immune cell. The disclosure also features methods of using the same, for example, for inhibiting immune responses when administered to a subject, such as to inhibit autoimmune reactions.

  该披露涉及孤立的多聚核苷酸，如编码破坏免疫细胞活性的多聚核苷酸，例如T细胞或B细胞活性的mRNA，包括包含一个或多个修饰的核碱基的mRNA。这些免疫细胞破坏多聚核苷酸编码一个包括第一个结构域的多肽，该结构域介导多肽与免疫细胞组分的结合，以及一个介导当多肽在免疫细胞中表达时抑制免疫细胞活性的第二结构域。该披露还涉及使用相同的方法，例如，将其用于向受试者施用时抑制免疫反应，例如用于抑制自身免疫反应。
• [EN] MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF<br/>[FR] ARNM CODANT DES POLYPEPTIDES DE MODULATION IMMUNITAIRE ET LEURS UTILISATIONS
  申请人：MODERNA TX INC

  公开号：WO2021076805A1

  公开（公告）日：2021-04-22

  The disclosure features lipid nanoparticle (LNP) compositions comprising immune modulating polypeptides and uses thereof. The LNP compositions of the present disclosure comprise mRNA therapeutics encoding immune modulating polypeptides, e.g., interleukin 2 (IL- 2) and/or granulocyte macrophage colony stimulating factor (GM-CSF). The LNP compositions of the present disclosure can stimulate T regulatory cells, e.g., increase the level and/or activity of T regulatory cells in vivo or ex vivo.

  披露了包含免疫调节多肽的脂质纳米粒子（LNP）组合物及其用途。本公开的LNP组合物包括编码免疫调节多肽的mRNA治疗药物，例如白细胞介素2（IL-2）和/或粒细胞巨噬细胞集落刺激因子（GM-CSF）。本公开的LNP组合物可以刺激T调节细胞，例如在体内或体外增加T调节细胞的水平和/或活性。
• The configuration at C-20 of a natural Δ⁵-C₂₆-sterol
  作者：John M. Joseph、William R. Nes

  DOI：10.1039/c39810000367

  日期：——

  The (20R)- and (20S)-epimers of halosterol, a naturally occurring C26-analogue of cholesterol, have been synthesized; the (20R)-epimer was identical with and the (20S)-epimer different from the sterol derived from the naturally occurring 22-dehydro derivative.

  合成了一种天然存在的胆固醇C 26类似物-甾醇的（20 R）和（20 S）表位；（20 R）-顶基与衍生自天然存在的22-脱氢衍生物的甾醇相同，而（20 S）-顶基与之不同。
• Dicarbofunctionalizations of an Unactivated Alkene via Photoredox/Nickel Dual Catalysis
  作者：Purusattam Dey、Sayan K. Jana、Pramod Rai、Biplab Maji

  DOI：10.1021/acs.orglett.2c02355

  日期：2022.9.2

  has been reported under photoredox/nickel dual catalysis. The mildness of the visible-light-mediated reaction allows the use of various alkyl and aryl electrophiles with several sensitive functional groups. The protocol was equally applied for late-stage diversification of drugs and biologically active molecules. Investigations elucidated the importance of photoredox/nickel dual catalysis and α-amino-radical-mediated

  已经报道了在光氧化还原/镍双重催化下未活化烯烃的 1,2-二碳官能化。可见光介导反应的温和性允许使用具有几个敏感官能团的各种烷基和芳基亲电子试剂。该协议同样适用于药物和生物活性分子的后期多样化。研究阐明了光氧化还原/镍双重催化和 α-氨基自由基介导的卤素原子转移的重要性，并为我们提供了参与反应的镍络合物。
• STEROL ANALOGS AND USES THEREOF
  申请人：ModernaTX, Inc.

  公开号：US20220402965A1

  公开（公告）日：2022-12-22

  The invention relates to compositions and methods for the preparation, manufacture, and therapeutic use of compositions comprising mRNA and a lipid nanoparticle comprising a compound of the invention and an ionizable lipid.

  本发明涉及包含mRNA和脂质纳米粒子的组合物的制备、制造和治疗用途的方法和组合物，所述脂质纳米粒子包括本发明的化合物和可离子化脂质。